1 / 47

Updates on the Management of CINV From the 2014 June Congresses

Updates on the Management of CINV From the 2014 June Congresses. Program Goals. Introduction. Introduction (cont). 3 Major Classes of Antiemetic Agents Used in CINV Prevention. Antiemetic Guidelines: Current Recommendations. NK-1 RAs: Aprepitant. Investigational NK-1 RAs.

kessie-garrett
Download Presentation

Updates on the Management of CINV From the 2014 June Congresses

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Updates on the Management of CINV From the 2014 June Congresses

  2. Program Goals

  3. Introduction

  4. Introduction (cont)

  5. 3 Major Classes of Antiemetic Agents Used in CINV Prevention

  6. Antiemetic Guidelines: Current Recommendations

  7. NK-1 RAs: Aprepitant

  8. Investigational NK-1 RAs

  9. Investigational NK-1 RAs (cont)

  10. Aprepitant vs Metoclopromide in Delayed CINV

  11. Rolapitant in Patients Receiving MECPhase 3 Study Design

  12. Rolapitant in Patients Receiving MECEfficacy Results

  13. Rolapitant in Patients Receiving MECSafety

  14. Rolapitant in Patients Receiving HECStudy Design of 2 Phase 3 RCTs

  15. Rolapitant in Patients Receiving HECEfficacy Results

  16. NEPA: A Fixed Dose Oral Combination of Netupitant and PalonosetronPrimary End Point Efficacy Results From 3 RCTs

  17. NEPA + DEX vs Oral PALO + DEX in AC-based MECMultinational, Randomized, Double-blind Phase 3 Study

  18. NEPA + DEX vs Oral PALO + DEX in AC-based MECOverall CR Rates Across Multiple Cycles

  19. NEPA + DEX vs PALO + DEX in AC-Based MECSafety Across Multiple Cycles

  20. NEPA + DEX vs PALO + DEX in AC-based MECMost Common TRAEs Across Multiple Cycles

  21. Non-AC MEC

  22. NEPA in Multicycle MEC and HECPhase 3 Study Design

  23. NEPA in Multicycle MEC and HECPatient Baseline and Disease Characteristics

  24. NEPA in Multicycle MEC and HEC Post-Hoc Analysis of No Emesis Rates (Cycle 1) in Patients Receiving Carboplatin

  25. Fosaprepitant in Non-AC MECPhase 3 Study Design

  26. APF530 vs Palonosetron

  27. Aprepitant in Pediatric PatientsPhase 3 Study Design

  28. The Problem of Nausea

  29. Summary

  30. Abbreviations

  31. Abbreviations (cont)

  32. References

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

  45. References (cont)

  46. References (cont)

More Related